Literature DB >> 22680981

Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study.

Magnus G Rasch1, Frederik N Engsig, Bo Feldt-Rasmussen, Ole Kirk, Gitte Kronborg, Court Pedersen, Jan Gerstoft, Niels Obel.   

Abstract

BACKGROUND: Impaired renal function is of major concern in human immunodeficiency virus (HIV)-infected patients.
METHODS: We used a mixed effects linear regression model to determine estimated glomerular filtration rates (eGFRs) in a population-based cohort of incident Danish HIV patients and stratified on baseline eGFR (eGFR(B)) < 90 and ≥ 90 ml/min per 1.73 m(2). Incidence rate ratios (IRRs) for chronic kidney disease (CKD) - 2 consecutive eGFR values < 60 ml/min per 1.73 m(2) measured > 3 months apart - were estimated (time-updated Cox-regression model).
RESULTS: The effect of time with HIV on eGFR was small in both strata (- 0.09 (95% confidence interval (CI) - 0.27, 0.09) and - 0.46 (95% CI - 0.64, - 0.27) ml/min per 1.73 m(2) per y). Treatment with tenofovir and indinavir was associated with lower eGFR in both strata: tenofovir - 2.00 (95% CI - 3.45, - 0.56) and - 1.94 (95% CI - 3.43, - 0.44) ml/min per 1.73 m(2) and indinavir - 2.14 (95% CI - 3.63, - 0.64) and - 3.29 (95% CI - 5.25, - 1.32) ml/min per 1.73 m(2). Nevirapine, atazanavir, and the combination of tenofovir and atazanavir were associated with lower eGFR in patients with eGFR(B) < 90 ml/min per 1.73 m(2). Highly active antiretroviral therapy (HAART) and exposure to tenofovir and atazanavir in combination were associated with CKD in patients with eGFR(B) < 90 ml/min per 1.73 m(2) (adjusted IRRs 6.08 (95% CI 2.76-13.41) and 26.75 (95% CI 9.54-75.05)).
CONCLUSION: Tenofovir and indinavir reduce eGFR, while time with HIV only has a modest effect on this parameter. Low eGFR(B) is associated with an increased risk of CKD, especially when receiving HAART regimens containing the combination tenofovir/atazanavir.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22680981     DOI: 10.3109/00365548.2012.673730

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  16 in total

1.  Changes in renal function with long-term exposure to antiretroviral therapy in HIV-infected adults in Asia.

Authors:  Kedar Joshi; David Boettiger; Stephen Kerr; Takeshi Nishijima; Kinh Van Nguyen; Penh Sun Ly; Man Po Lee; Nagalingeswaran Kumarasamy; Wingwai Wong; Pacharee Kantipong; Do Duy Cuong; Adeeba Kamarulzaman; Jun Yong Choi; Fujie Zhang; Romanee Chaiwarith; Oon Tek Ng; Sasisopin Kiertiburanakul; Benedict Lim Heng Sim; Tuti Parwati Merati; Evy Yunihastuti; Rossana Ditangco; Jeremy Ross; Sanjay Pujari
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-09-24       Impact factor: 2.890

2.  Prevalence of renal disease within an urban HIV-infected cohort in northern Italy.

Authors:  Leonardo Calza; Elisa Vanino; Eleonora Magistrelli; Caterina Salvadori; Alessandra Cascavilla; Vincenzo Colangeli; Maria Assunta Di Bari; Roberto Manfredi; Pierluigi Viale
Journal:  Clin Exp Nephrol       Date:  2013-05-28       Impact factor: 2.801

3.  Incidence of stage 3 chronic kidney disease and progression on tenofovir-based regimens.

Authors:  Hadas Zachor; Rhoderick Machekano; Michelle M Estrella; Peter J Veldkamp; Michele D Zeier; Olalekan A Uthman; Jantjie J Taljaard; Mohammed R Moosa; Jean B Nachega
Journal:  AIDS       Date:  2016-05-15       Impact factor: 4.177

Review 4.  Differentiating HIV-associated nephropathy from antiretroviral drug-induced nephropathy: a clinical challenge.

Authors:  Neelja Kumar; Mark A Perazella
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.495

5.  Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review.

Authors:  Corinne Isnard Bagnis; Hans-Jürgen Stellbrink
Journal:  Infect Dis Ther       Date:  2015-01-08

6.  Atazanavir nephrotoxicity.

Authors:  Masaki Hara; Akihiko Suganuma; Naoki Yanagisawa; Akifumi Imamura; Tsunekazu Hishima; Minoru Ando
Journal:  Clin Kidney J       Date:  2015-03-20

7.  Smoking and renal function in people living with human immunodeficiency virus: a Danish nationwide cohort study.

Authors:  Magnus Glindvad Ahlström; Bo Feldt-Rasmussen; Rebecca Legarth; Gitte Kronborg; Court Pedersen; Carsten Schade Larsen; Jan Gerstoft; Niels Obel
Journal:  Clin Epidemiol       Date:  2015-08-28       Impact factor: 4.790

8.  Renal Function in Chinese HIV-Positive Individuals following Initiation of Antiretroviral Therapy.

Authors:  Yan Zhao; Mingjie Zhang; Cynthia X Shi; Yao Zhang; Weiping Cai; Qingxia Zhao; Yong Li; Huiqin Li; Xia Liu; Limeng Chen; Ye Ma; Fujie Zhang; Zhongfu Liu; Zunyou Wu
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

Review 9.  Managing dyslipidemia in HIV/AIDS patients: challenges and solutions.

Authors:  Nazik Elmalaika Os Husain; Mohamed H Ahmed
Journal:  HIV AIDS (Auckl)       Date:  2014-12-17

10.  Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.

Authors:  Nicola Gianotti; Laura Galli; Andrea Poli; Stefania Salpietro; Silvia Nozza; Alessia Carbone; Marco Merli; Marco Ripa; Adriano Lazzarin; Antonella Castagna
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.